Products in Development

Targeting multiple tumor types

The Novartis Oncology pipeline includes compounds in all phases of development, starting with preclinical studies in tumor cell line and animal models through large Phase III randomized trials.

Everolimus is a particularly promising oral kinase inhibitor now being investigated in Phase I to III clinical trials in multiple tumor types, including neuroendocrine tumors, renal cell carcinoma, and colorectal, lung, and breast cancers.

A Pipeline That Spans All Phases

Click on the compound name below to learn more. 

*Subject to an agreement between Novartis Oncology and Xoma.
**INC280 (also known asINCB028060) is licensed from Incyte Corp.
◊ Also known as TKI258
†Also known as LBH589
‡ Aggressive systemic mastocytosis
° Hodgkin lymphoma
§ ASA404 (vadimezan, formerly known as AS1404, DMXAA) is licensed from Antisoma
ˇ Tuberous sclerosis complex
^a Multiple Myeloma
~ INC424 is being developed in collaboration with Incyte Corp. and Novartis AG. Novartis AG has licensed the rights to INC424 outside the United States. Incyte maintains the rights within the United States

From targeted therapy to cytotoxics...
the Novartis pipeline encompasses a broad spectrum of approaches.

Phase I solid tumors targeting mTOR/PI3K (BEZ235, BGT226), PI3K (BKM120), IAP (LCL161), Smoothened (LDE225), Hsp90 (AUY922), FGFR (BGJ398), C-Met (INC280***), DKK1 (BHQ880).

*ASA404 (vadimezan, formerly known as AS1404, DMXAA) is licensed from Antisoma.
**Also known as TKI258.
***INC280 (also known as AS1404, DMXAA) is licenced from Incyte Inc.
†Also known as LBH589.
‡ Aggressive systemic mastocytosis.
§ Subject to an agreement between Novartis Oncology and XOMA.
±INC424 also known as INCB018424 is being developed collaboratively by Incyte and Novartis AG. Novartis AG has licenced the rights to INC424 outside the United States. Incyte maintains the rights within the United States.

All compounds or uses are investigational. Efficacy and safety have not been established. There is no guarantee that they will become commercially available.